Drug cost distribution by drug type in public drug plans Canada 2017/2018

This analysis only includes data for beneficiaries that met their deductible and received public reimbursement. Direct-acting antiviral (DAA) drugs are used in the treatment of hepatitis C. High-cost drugs have an average annual treatment cost of greater than $10,000 and include both biologics and non-biologics.
Included are: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and the Non-Insured Health Benefits Program.
* The patented medicines market segment includes all medicines that had patent protect at some time during in the period of study, even if the patent expired during that period. As such, the 2017/18 growth does not reflect the loss of patent exclusivity for some top-selling medicines over the course of the fiscal year.
** This market segment includes devices, compounded drugs, and other products that are reimbursed by public drug plans but do not have a Health Canada assigned Drug Identification Number (DIN).